Imperative Care has closed an oversubscribed $100 million convertible note financing round to support both the commercialization of its existing thrombectomy technologies and the development of its endovascular robotics platform, Telos. The round was co-led by Elevage Medical Technologies, a Patient Square Capital platform, and Perceptive Advisors, with participation from existing investor Catalio Capital Management.
As part of the financing, Dr. Evan Melrose, CEO of Elevage Medical Technologies, will join Imperative Care’s Board of Directors, signaling increased strategic focus on scaling advanced medical technologies and navigating regulatory pathways associated with robotic systems.
Imperative Care operates as a commercial-stage medical technology company specializing in thromboembolic disease, targeting severe blood clots in arteries and veins. Its current portfolio—including the Zoom, Symphony, and Prodigy Thrombectomy Systems—has been used in more than 78,000 procedures globally, establishing a foundation in minimally invasive stroke intervention.
A central component of the new funding will be directed toward the development of the Telos platform, an endovascular robotic system designed to enhance precision and consistency in vascular procedures. The system aims to replace manual catheter manipulation with robotic-assisted navigation, enabling sub-millimeter accuracy in complex neurovascular pathways.
The approach is intended to address limitations in current thrombectomy procedures, particularly variability in outcomes and first-pass success rates. By improving control and standardization, the platform is expected to support faster clot removal and more consistent restoration of blood flow.
Beyond procedural precision, the Telos system reflects a broader objective of expanding access to stroke care. Current treatment models often require patients to be transported to specialized centers with trained neurointerventionalists. A robotic-assisted and potentially remote-enabled system could reduce geographic disparities by enabling more providers to perform these procedures.
The company indicated that standardizing thrombectomy workflows through robotics could make training more scalable and open the possibility for remote intervention models in the future.
With this financing, Imperative Care is positioning itself at the intersection of interventional neurology and medical robotics, aiming to advance both clinical outcomes and accessibility in stroke treatment.
Click here for the original news story.